The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A pilot phase II trial of neoadjuvant camrelizumab plus nab-paclitaxel and cisplatin (NeoCPC) for locoregionally advanced, resectable squamous cell carcinoma of the head and neck.
 
Di Wu
Research Funding - Jiangsu Hengrui Pharmaceuticals (Inst)
 
Yong Li
Research Funding - Jiangsu Hengrui Pharmaceuticals (Inst)
 
Peng-Fei Xu
Research Funding - Jiangsu Hengrui Pharmaceuticals (Inst)
 
Xinrui Zhang
Research Funding - Jiangsu Hengrui Pharmaceuticals (Inst)
 
Hongsheng Lin
Research Funding - Jiangsu Hengrui Pharmaceuticals (Inst)
 
Yin Li
Research Funding - Jiangsu Hengrui Pharmaceuticals (Inst)
 
Qi Fang
Research Funding - Jiangsu Hengrui Pharmaceuticals (Inst)
 
Fei Cao
Research Funding - Jiangsu Hengrui Pharmaceuticals (Inst)
 
Yong Su
Research Funding - Jiangsu Hengrui Pharmaceuticals (Inst)
 
Li-Xia Lu
Research Funding - Jiangsu Hengrui Pharmaceuticals (Inst)
 
Yizhuo Li
No Relationships to Disclose
 
Zheng Zhao
Research Funding - Jiangsu Hengrui Pharmaceuticals (Inst)
 
Xiaoyu Hong
No Relationships to Disclose
 
Guohong Li
No Relationships to Disclose
 
Honghong Yan
Research Funding - Jiangsu Hengrui Pharmaceuticals (Inst)
 
Yunyun Fan
Research Funding - Jiangsu Hengrui Pharmaceuticals (Inst)
 
Lei Chen
No Relationships to Disclose
 
Zhiming Li
Research Funding - Jiangsu Hengrui Pharmaceuticals (Inst)
 
Xuekui Liu
Research Funding - Jiangsu Hengrui Pharmaceuticals (Inst)